A Phase II Study of Ibrutinib, Rituximab and mini-CHOP therapy in very elderly patients with newly diagnosed diffuse large b-cell lymphoma (DLBCL)
Researchers
- Professor Dipti Talaulikar (Primary Investigator)
Grant status
Completed-Pending ReportsGrant start date
01/07/2017Grant funding
- 2016: $87,470 from Australasian Leukaemia and Lymphoma Group
- 2019: $52,063 from Australasian Leukaemia and Lymphoma Group
- 2020: $52,063 from Australasian Leukaemia and Lymphoma Group
- 2021: $52,063 from Australasian Leukaemia and Lymphoma Group